1055 / 1851
PD-L1
expression is a
prognostic factor
in resected NSCLC and a
predictive factor for efficacy
of therapies targeting PD-1 and
PD-L1 in metastatic NSCLC.
The
prognostic value of PD-L1
expression in patients with
NSCLC treated with radiotherapy
(RT) and
chemotherapy
(CT)
has
not been explored
.
Tumor
immune microenvironment is involved
in
mechanisms underlying
efficacy of RT and CT
, suggesting that
PD-L1 expression may modulate response to these treatments.
Randomized data needed due to lack of historical baseline
and recent stage migration
PD-1 inhibitors and RT